BioXcel Therapeutics to Participate in Two Upcoming Investor Conferences
BioXcel Therapeutics, Inc. (BTAI) announced that Dr. Vimal Mehta will participate in fireside chats at two virtual investor conferences.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
BioXcel Therapeutics, Inc. (BTAI) announced that Dr. Vimal Mehta will participate in fireside chats at two virtual investor conferences. The first event, the BMO 2020 Prescriptions for Success Healthcare Conference, will take place on June 23, 2020, at 8:30 AM ET. The second event, the BofA Securities Napa Biopharma Conference, is scheduled for June 24, 2020, at 7:30 AM PT (10:30 AM ET). Live webcasts will be available on the company’s website, with archives accessible for at least 30 days.
Details
News Market Reaction – BTAI
The recorded move for BTAI in the trading session of this news was +0.30%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
NEW HAVEN, Conn., June 15, 2020 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (“BTI” or the “Company”) (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial intelligence to identify improved therapies in neuroscience and immuno-oncology, today announced that Dr. Vimal Mehta, Founder and Chief Executive Officer of BTI, will participate in fireside chats at two upcoming virtual investor conferences.
Presentation Details:
Event: BMO 2020 Prescriptions for Success Healthcare Conference
Date: Tuesday, June 23, 2020
Time: 8:30 AM ET
Event: BofA Securities Napa Biopharma Conference
Date: Wednesday, June 24, 2020
Time: 7:30 AM PT/10:30 AM ET
Live webcasts from the BMO and BofA fireside chats will be accessible through the Investors section of the Company's website at www.bioxceltherapeutics.com. Following the conference, the webcast will be archived on the BioXcel Therapeutics, Inc. website for at least 30 days.
About BioXcel Therapeutics, Inc.:
BioXcel Therapeutics, Inc. is a clinical stage biopharmaceutical company utilizing artificial intelligence to identify improved therapies in neuroscience and immuno-oncology. BTI's drug re-innovation approach leverages existing approved drugs and/or clinically evaluated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices. BTI's two most advanced clinical development programs are BXCL501, an investigational sublingual thin film formulation in development for acute treatment of agitation resulting from neuropsychiatric disorders, and BXCL701, an investigational orally administered systemic innate immunity activator in development for treatment of a rare form of prostate cancer and for treatment of pancreatic cancer in combination with other immuno-oncology agents. For more information, please visit www.bioxceltherapeutics.com.
Contact Information:
BioXcel Therapeutics, Inc.
www.bioxceltherapeutics.com
Investor Relations:
John Graziano
jgraziano@troutgroup.com
1.646.378.2942
Media:
Julia Deutsch
jdeutsch@troutgroup.com
1.646.378.2967
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.